Source comparison
TB-500 Research Longevity: Comparison by Protocol Design
Continuous 2×/week dosing (2mg/kg) 24 weeks Wound closure rate: +38% vs baseline at week 8, +22% at week 24 48% reduction in actin-polymerization response vs week 8 50% regression within 4 weeks of stopping Effective short-term but unsustainable. Receptor dese
This comparison does not assign a generated winner or score.
- Continuous 2×/week dosing (2mg/kg)
- 24 weeks
- Wound closure rate: +38% vs baseline at week 8, +22% at week 24
- 48% reduction in actin-polymerization response vs week 8
- 50% regression within 4 weeks of stopping
- Effective short-term but unsustainable. Receptor desensitization limits long-term use
- Cyclic 8-on/4-off (2mg/kg, 2×/week during on-cycles)
- 36 weeks
- Capillary density: +40% maintained across all measurement points
- 85% of initial response preserved at week 36
- Minimal regression during 4-week breaks, 70% retention 8 weeks post-cessation
- Optimal for sustained protocols. Balances efficacy with receptor preservation
- Once-weekly maintenance (1mg/kg after 8-week loading)
- 52 weeks
- Collagen fiber alignment: +28% vs baseline, stable weeks 12–52
- 68% of peak response maintained
- Gradual decline over 12 weeks, 40% retention at 12 weeks post-cessation
- Suitable for low-intervention longevity. Slower gains but better tolerance
- High-dose loading only (5mg/kg, 3×/week for 6 weeks, then stop)
- 6 weeks active, 18 weeks follow-up
- Dermal thickness: +52% at week 6
- Not applicable. Dosing stopped
- Complete regression by week 18
- Ineffective for longevity. No sustained benefit without maintenance